Singapore Paincare (SGX:FRQ) disclosed a qualified opinion from auditors BDO LLP for its financial statements for the year ended June 30, 2024, according to a Thursday filing on the Singapore Exchange.
The group's goodwill, valued at $13.5 million, was assessed for impairment using a value-in-use method, with no impairment loss recognized. The assessment of investments in subsidiaries, totaling around $5 million, also showed no impairment loss.
Additionally, the fair value of financial assets held by the group's joint venture, Singapore Paincare Capital, was recorded at about $8.8 million, contributing to a fair value gain of $578,000.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.